STAT3 and cancer: Next, to investigate whether IL6-dependent STAT3 activation is essential for CALB2 expression in cancer cells, various concentrations of stattic (MCE, #HY-13818), a potent STAT3 inhibitor, were added to the cancer cells with rhIL6 treatment.